本文選題：血管免疫母細(xì)胞性T細(xì)胞淋巴瘤　切入點(diǎn)：臨床特征　出處：《臨床腫瘤學(xué)雜志》2017年03期 　論文類型：期刊論文

【摘要】：目的探討血管免疫母細(xì)胞性T細(xì)胞淋巴瘤(AITL)的臨床特征和預(yù)后因素。方法回顧性分析安徽醫(yī)科大學(xué)第一附屬醫(yī)院2009年2月至2016年6月收治的39例AITL患者的臨床資料。39例AITL患者治療均采用全身化療,其中29例行標(biāo)準(zhǔn)CHOP方案,化療2個(gè)周期后評(píng)價(jià)客觀療效。采用Kaplan-Meier方法進(jìn)行生存分析,各亞組間的比較采用Logrank檢驗(yàn)。結(jié)果 39例患者中位發(fā)病年齡為62歲,男女比例為2.5∶1,Ann Arbor分期Ⅲ~Ⅳ期者30例,ECOG評(píng)分1者13例,乳酸脫氫酶(LDH)升高者29例,β2微球蛋白(β2-MG)升高者20例,低白蛋白水平者19例,淋巴細(xì)胞數(shù)增多者19例,結(jié)外侵犯數(shù)目1者12例,有漿膜腔積液者16例,Ki-67≥50%者11例,IPI評(píng)分2~5者33例。全組患者獲完全緩解(CR)9例,部分緩解(PR)14例,有效率(RR)為58.9%。全組患者預(yù)期1、2、3年生存率分別為81%、59%、40%,中位OS為27個(gè)月(95%CI:15.139~38.861個(gè)月),中位PFS為9個(gè)月(95%CI:1.317~16.683個(gè)月)。單因素分析顯示,ECOG評(píng)分1、結(jié)外侵犯數(shù)目1、有漿膜腔積液、Ki-67≥50%與AITL患者的不良預(yù)后相關(guān)。結(jié)論 AITL是一種侵襲性強(qiáng)、預(yù)后不良的疾病。患者治療前ECOG評(píng)分、結(jié)外侵犯數(shù)目、是否存在漿膜腔積液和Ki-67水平可作為其預(yù)后的參考因素。
[Abstract]:Objective to investigate the clinical features and prognostic factors of vascular immunoblastic T-cell lymphoma (AITL). Methods the clinical data of 39 patients with AITL admitted from February 2009 to June 2016 in the first affiliated Hospital of Anhui Medical University were retrospectively analyzed. Materials. 39 patients with AITL were treated with systemic chemotherapy. 29 cases were treated with standard CHOP regimen, objective curative effect was evaluated after 2 cycles of chemotherapy, survival analysis was performed by Kaplan-Meier method and Logrank test was used to compare the subgroups. Results the median onset age of 39 patients was 62 years old. The ratio of male to female was 2.5: 1 Ann Arbor stage 鈪，

本文編號(hào)：1580393